Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS.-H.I. Ou, Gregory J. Riely, Cynthia Huang Bartlett et al.|Annals of Oncology|2014Cited by 221